Recap: Spero Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Spero Therapeutics (NASDAQ:SPRO) reported Q3 earnings with an EPS of $-0.06, missing estimates by 100% compared to the expected $-0.03. Revenue increased by $23.47 million from the same period last year. In the previous quarter, SPRO beat EPS estimates but the share price fell by 3.45% the following day.
November 13, 2023 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Spero Therapeutics reported a larger loss per share than expected in Q3, with an EPS of $-0.06 versus the estimated $-0.03, but showed a significant increase in revenue from the previous year.
Missing earnings estimates typically has a negative impact on stock prices in the short term. Although revenue has increased, the miss on EPS is likely to weigh more heavily on investor sentiment, especially considering the stock price dropped after beating estimates last quarter.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100